Latest Breaking News On - Rachelle babb - Page 1 : comparemela.com

Ratio Therapeutics Announces $50M Series B Financing to Advance Targeted Radiotherapies for Cancer Treatment

Ratio Therapeutics Announces $50M Series B Financing to Advance Targeted Radiotherapies for Cancer Treatment
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRachelle babbMey boukennaJohn babichStephen pagliucaJack hoppinRusso partnersSecurities exchangeTechnology licensing at cornell universityPrnewswire ratio therapeutics incRatio therapeutics incBristol myers squibbMore thanTechnology licensingChief executiveSecurities act

Emergex Announces R&D Collaboration with DEKA Research &

Emergex has entered into an agreement with DEKA Research & Development (‘DEKA’) to assess the compatibility of Emergex’s T cell-priming set-point.

United kingdomUnited statesLaurens rademacherRachelle babbStorme moore thornicroftEmergex denguetcDean kamenResearch development corpResearch developmentEmergex vaccines holding limitedIntradermal therapeuticIntradermal therapeutic applicatorVaccines holding limitedChief technology officerTherapeutic applicatorDengue fever

Emergex Announces R&D Collaboration with DEKA Research & Development Corp for

Emergex has entered into an agreement with DEKA Research & Development (‘DEKA’) to assess the compatibility of Emergex’s T cell-priming set-point immunotherapeutic candidates with DEKA’s Intradermal Therapeutic Applicator. The collaboration

United statesUnited kingdomStorme moore thornicroftDean kamenLaurens rademacherEmergex denguetcRachelle babbResearch developmentEmergex vaccines holding limitedResearch development corpIntradermal therapeuticIntradermal therapeutic applicatorVaccines holding limitedChief technology officerTherapeutic applicatorDengue fever

Emergex Announces Authorisation from Philippines FDA to Initiate Phase I-II Clinical Trial of CoronaTcP™

Emergex received authorisation from the Philippines FDA to launch a Phase I-II clinical trial of CoronaTcP, its T cell-priming immune set-point ca.

United statesUnited kingdomRachelle babbStorme moore thornicroftThomas rademacherPhilippines food drug administrationEmergex vaccines holding limitedVaccines holding limitedPhilippines foodDrug administrationChief executive officerDengue feverUniversal influenzaSenior account

Emergex and Brazil s IBMP Announce Clinical Development Collaboration for T Cell-Priming Immune Set-Point Candidates - Brazil Business Today

Emergex and Brazil’s IBMP to co-fund Phase II and Phase III studies of Emergex’s Dengue Fever and Betacoronavirus T cell-priming immune set-point therapeutic

United statesEstado do rioUnited kingdomStorme moore thornicroftPedro ribeiro barbosaThomas rademacherRachelle babbSteering committeeMinistry of healthMolecular biology institute of paranEmergex vaccines holding limitedIndustrial complex of health complexo econDengue feverVaccines holding limitedMolecular biology instituteJoint steering committee